There are numerous reports about a potentially seismic court ruling that affects how pharma companies discuss off-label use of their products under FDA restrictions. A Federal court held that the Food and Drug Administration cannot prevent Amarin Pharma Inc. from marketing its fish-oil product for an off-label use, so long as its claims are truthful, according to a Wall Street Journal report.
According to the New York Times, the decision “could inhibit the ability of the F.D.A. to regulate one aspect of pharmaceutical marketing.” Judge Paul Engelmeyer wrote that the agency “may not bring such an action based on truthful promotional speech alone, consistent with the First Amendment.”
Medical Marketing & Media reports that the decision “bolsters the pharmaceutical industry’s case against current off-label marketing restrictions.” Moreover, “the case has wider implications for the industry and will likely add force to ongoing efforts to change what are widely considered outdated regulations.”
The Washington Post Wonkblog reported that “the judge’s decision does require that the off-label promotion of a drug not be misleading,” adding that the decision “also opens up the question of who adjudicates whether unapproved uses of a drug are truthful.”
From the news release of the American Association for Justice.


